Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis. Issue 9 (19th September 2022)

• Record Type: Journal Article
• Authors: Lakritz, Stephanie; Forsberg, Peter A.; Sherbenou, Daniel W.; Mark, Tomer M.
• Is Part Of: Clinical case reports. Volume 10:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-19
• Subjects: chemotherapy -- oncology -- pharmacology -- plasma cell neoplasms; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.6199
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who developed evidence of an autoimmune enteropathy shortly after initiating lenalidomide based therapy. Abstract : Lenalidomide may increase risk for a variety of autoimmune complications, use in at‐risk patients should be accompanied by close monitoring. This is the first reported case of an autoimmune enteropathy developing after initiation of lenalidomide.